SCHEMBL14736800

SCHEMBL14736800

COc1ccc(-c2cccc3c2CCC3=O)c(OC(=O)CCC2CCCC2)c1OC

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 2/20 0.41
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
PDE4D Q08499 1/20 0.38
GAA P10253 1/20 0.38
HDAC4 P56524 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14738016 0.90 HPGD (0.49) HPGDALDH1A1KDM4ETDP1L3MBTL1
SCHEMBL14737262 0.86 ALDH1A1 (0.53) HPGDALDH1A1KDM4EPDE4DGAA
SCHEMBL2596081 0.85 HPGD (0.41) HPGDALDH1A1KDM4ETDP1NPSR1
SCHEMBL2588768 0.84 ALDH1A1 (0.51) HPGDALDH1A1KDM4EPDE4DGAA
SCHEMBL14738339 0.84 ALDH1A1 (0.51) HPGDALDH1A1KDM4EPDE4DGAA
SCHEMBL2593158 0.83 ALDH1A1 (0.56) HPGDALDH1A1KDM4EPDE4DGAA
SCHEMBL14737325 0.83 ALDH1A1 (0.50) HPGDALDH1A1KDM4EPDE4DGAA
SCHEMBL14737280 0.83 HPGD (0.52) HPGDALDH1A1KDM4EPDE4DHDAC4
SCHEMBL14737219 0.83 HPGD (0.52) HPGDALDH1A1KDM4EPDE4DHDAC4
SCHEMBL14737845 0.83 ALDH1A1 (0.52) HPGDALDH1A1KDM4ENPSR1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US claimed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A HPGD 1088/4885ALDH1A1 824/4885KDM4E 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.